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Abstract In 2003, the United Kingdom and Japan had adopted relatively similar approaches to
human embryonic stem cells science. The decade since has witnessed significant divergence in their
national policies as differing responses to ethical questions about research use of human embryos
emerged. The United Kingdom pursued a vision of ‘institutionally accredited stem cells’ by reconfi-
guring the role of the Human Fertilisation and Embryology Authority and establishing the UK Stem
Cell Bank. In contrast, Japan followed a vision of ‘technically advanced stem cells’ by developing
induced pluripotent stem cells and supporting its research programs enthusiastically. Our research –
drawing upon extensive fieldwork in both countries – demonstrates the socio-technical arrange-
ments developed to instantiate these visions and articulates their divergence while at the same time
revealing their connectedness. This relationship becomes progressively evident as the two visions
face each other in the politics of standardization in global stem cell science. Drawing on Franklin’s
concept of local/global biological, we discuss the connectedness of the two local arrangements. In so
doing, we explicate the future challenges for both countries as they need to demonstrate the sig-
nificance of their visions in this global enterprise, while the success of one would likely undermine
the significance of the other.
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Introduction
In 2003, the UK Royal Academy of Engineering sent a mission to Japan resulting in the report
“The Japanese Approach to Tissue Engineering”. The mission identified familiar ethical issues
about using human embryonic stem (hES) cells for research purposes as a major obstacle, and
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in it they state that “there is no doubt that Japan faces very similar barriers to the successful
commercial introduction of tissue engineering products and processes to those experienced in
the UK and elsewhere” (Royal Academy of Engineering (UK) (RAoE), 2003, p. 3). While we
agree with this statement from a 2003 perspective, in this article we argue the two countries
subsequently took quite different approaches to dealing with the embryo issue, each of them
underpinned by a globally recognized socio-technical arrangement: in the United Kingdom, the
Human Fertilisation and Embryology (HFE) Act amendments and establishment of the UK
Stem Cell Bank, and in Japan, the development of induced pluripotent stem (iPS) cells and the
subsequent policy shift. Both of these arrangements attracted the attentions of many other
countries, and have been adopted in some, including the establishment of national stem cell
banks in Spain and the promotion of iPS cell research in the United States (Stephens et al, 2011a,
2013; Hammond-Browning and Stephens, 2013). Our analysis, however, reveals not only that
these socio-technical arrangements take different forms framed by their national context but
also that they pose serious challenge to each other at an international level, where they have to
prove their global significance, allowing their stem cells to travel beyond their locality.
In this article we elaborate on this challenge through an analysis of practical, scientific and
regulatory responses observed in the two countries before and after the development of human
iPS cells in 2007. We choose these two countries because they represent international
leadership in their respective socio-technical arrangements. We use this notion of socio-
technical arrangements to capture the assemblage of institutional, symbolic, material and
imagined practices that constitute what Franklin (2005) terms the “local biologicals” pursued
in each country. To Franklin, stem cells can be understood as a global/local biological:
[Stem cell] production is a global biological enterprise, but it is also their “global,” in the
sense of totalizing, projected uses to which this term refers. […] Stem cell technology is a
prime example of the ways in which the global may come into being as a biocultural
condition, as a form of identity, and as a realm of imaginary futures. At the same time,
stem cell technology is also … a local biological. […] Stem cell technologies […]
demonstrate how biological properties are increasingly not only being “discovered,” but
are being created, in ways that reveal specific national and economic priorities, moral
and civic values, and technoscientific institutional cultures.
(Franklin, 2005, p. 61)
By seeing a local biological as an assemblage, our analysis premises on the view that the local
priorities and values it reflects can be heterogeneous and contested within its original context,
and are also influenced by other local biologicals created elsewhere due to the globalizing
nature of stem cell science and the complex flows of actors, institutions and narratives as its
consequence. Therefore, the aims of this article are first to make explicit the specific priorities
and values in the two countries and then to reveal the practical challenges in negotiating their
differences and instantiating them in both local and global contexts.
The analysis divides into three sections. The first details the history until 2007, focusing upon
the divergent trajectories taken in Japan and the United Kingdom, and the second examines the
initial responses to iPS cell technology in both countries. Together these two sections
demonstrate how the two nations attempt to instantiate their visions of ‘institutionally
accredited stem cells’ in the United Kingdom and ‘technically advanced stem cells’ in Japan.
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The third section then develops the work of Hauskeller and Weber (2011) and Eriksson and
Webster (2008) to articulate how these two socio-technical arrangements pose challenges for
each other as we reveal the politics of standardization in international stem cell science. We
necessarily adopt a slightly different tone for narrating the history in the first two sections from
the discussion in the third section. In the first two sections we draw together the analysis of
narrative data from policy documents, observations and interviews to report meanings and
practices as produced by actors in the field. In the final section the onus shifts toward articulating
our own original contribution by applying existing theory from Science and Technology Studies
to allow us, as analysts, to speculate on future practice.
To preview our argument in succinct form, by 2003 both Japan and the United Kingdom
attempted to provide a regulatory foundation for hES cell research that was both mindful of
ethical concerns over embryo use while permissive and facilitative of an emerging stem cell
bioeconomy. While the United Kingdom experienced a level of success through adapting
existing regulatory structures and establishing the UK Stem Cell Bank, internal rigidities
within the Japanese system prevented all but small quantities of hES cell research occurring.
The stagnated Japanese stem cell research portfolio was radically transformed with the
emergence of iPS cells as Japan reconfigured its vision for stem cell research and rapidly
adjusted its institutional and regulatory system. While many UK scientists also engaged with
iPS cell research, the institutional vision at nation-state level, and the administrative forms it
supported, remained largely focused upon hES cell research. In contrast, stem cell research in
Japan exhibited rapid expansion in iPS cell research since 2007 while the stagnation of hES
cell research remained persistent. In doing so, these locally specific biological arrangements
are progressively posing challenges to each other as they attempt to globalize, meaning both to
internationalize and to totalize, their socio-technical arrangements. One of the battlefields for
this contestment is to be found in the seemingly benign realm of standardization. In practice,
as we demonstrate, while both approaches to stem cell science diverted off into different
directions, both Japanese and UK researchers and institutional actors must respond to the
ethical and technical potentials of the other, as iPS and hES cells, and the standardization
procedures pursued with both, are used as referencing points by which the other is judged and
notions of ‘naturalness’ and ‘efficacy’ are contested. These challenges now demand each of the
countries engage with the approach that the other pursued earlier: a technical characterization
of hES cells for the United Kingdom and an institutional validation of iPS cells for Japan.
Methodology
This article builds on two separate projects and we draw upon empirical data collected in
them both. The first, conducted by Mikami, was a 3-year comparative interview study of
tissue engineering in the United Kingdom and Japan. Mikami conducted 72 interviews with
UK and Japanese scientists, regulators and other individuals engaged in the field. The second,
conducted by Stephens, is a 3-year ethnographic study of the UK Stem Cell Bank that
conducted observations and 36 interviews with staff at the bank, its guidance committee,
regulatory bodies and laboratories that deposit stem cell lines at the Bank. These intensive
data collection periods in the mid-to-late 2000s have been supplemented with continued
engagement with the field up to the present date. Interviews and documents in Japanese have
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been translated into English and analyzed by the first author. The data were first analyzed
individually by the two authors and narratives of stem cell science in each of the two countries
were studied. Comparing these country-specific narratives then allowed us to identify (i) the
key instances in which their socio-technical arrangements were being (re-)shaped, and (ii)
exactly what form this (re-)shaping took. We subsequently returned to our data focusing on
grand narratives in both countries to arrive at the argument presented here.
The detailed qualitative analysis conducted inevitably gave rise to nuanced and complicated
accounts of practice in each nation. In writing we are mindful of balancing these situated and
sometimes contradictory accounts with the broader analytical framework of grand narratives
emerging in both local and global biologicals. It is for this reason that we embed a notion of
‘heterodoxy within’ on conceptualization of local biologicals. This concern also frames the
form of our analysis as the level of analysis we pursue involves conveying and comparing the
grand narratives in each country without denying their local contestment. Such contestment is
highlighted only when it is critical for explicating the connectedness of the two local
biologicals in this article.
In our analysis, we worked with detailed and lengthy interview extracts ensuring our
analysis responds closely to the contingency and complexity of these accounts. In reporting the
interview data, however, we decided to keep it succinct and precise, using only interview data
that work as clear articulations of core themes found in the data. Our decision was (i) to retain
our focus on grand narratives, as stated earlier, and also (ii) to retain an appropriate quantity
of interview material for the size and scope of our report.
We recognize, of course, that the United Kingdom and Japan are not the only countries
active in stem cell research, and are not the only countries engaged in pursuing local and
global aspirations in regenerative medicine. However, they do provide a sharp point of
comparison around which we can develop our analytical framework. We are aware of the
inherent challenge in basing our account on a comparison of two nations both operating
within an international context. This challenge can be especially significant when comparing
one ‘Western’ and one ‘non-Western’ country, that is, the United Kingdom and Japan,
respectively. Such accounts can risk constructing Japan as a ‘victim’ of some form of Western
imperialist strategizing (see, for example, Lock, 2002 for discussion of this risk). We avoid
doing this as much as possible by focusing on individual countries in the earlier stage of our
analysis. At the same time, we deliberately leave any sense of Western imperialism, or the
aspiration in Japan to challenge such imperialism, in this article where the actors in our study
themselves used such narratives.
2001–2007: A Shared Vision Unevenly Pursued
The 2003 Royal Academy of Engineering report suggests that Japan and the United Kingdom
faced a set of similar challenges. The two governments recognized tissue engineering, or
regenerative medicine, as an important innovation, a basis of regaining economic strength, and a
potential mechanism for addressing the health issues of their aging populations. Both governments
recognized the ongoing political and ethical debates about appropriate hES cell use. During their
5-day visit to Japan, the members of the mission visited two ministries, five research groups
and five private companies. While they were impressed by the scale of investment the Japanese
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government had made, they also judged its target to be unreasonably high, particularly noting
that its investment had built world-class facilities but had not attracted world-class
researchers. They were also concerned about the low level of private investment in the field,
and pointed to uncertainties about how the technology would be utilized in clinical contexts.
Furthermore, the mission observed that Japanese researchers tended to focus on the basic
biology of stem cells, such as cell development, as opposed to engineering aspects, such as
developing therapeutic products.
In 2001, both the United Kingdom and Japan were in the early stages of developing a
regulatory structure to support a vision of productive but ethical stem cell science. The UK
government had officially approved the use of human embryos for research purposes under
strict conditions in as early as the 1990s and formed its regulatory structure building upon
them (Hauskeller, 2004). The 1990 HFE Act legalized research use of human embryos for a
limited set of five specific purposes (Department of Health (UK) (DoH), 1990, Schedule 2:
Paragraph 3(2)). The Act invokes a concept of “early embryos”, meaning “embryos before the
appearance of the primitive streak” as observed on day 14 of development, as originally
suggested in the Warnock Report of 1984 (cf. Mulkay, 1997). This first Act was focused upon
reproductive health, but the raised attention on embryo research inspired by Thompson’s
1998 derivation of the first hES cell line provoked a 2001 amendment to extend the scope of
legitimate research to include:
(1) increasing knowledge about the development of embryos;
(2) increasing knowledge about serious diseases; and
(3) enabling any such knowledge to be applied in developing treatments for serious
disease.
(DoH, 2001, Paragraph 2(2))
It resulted in a UK regulatory system recognized as both (i) highly regulated in that all hES cell
derivation had to gain approval from the Human Fertilisation and Embryology Authority
(HFEA), and later that all hES cell research had to gain approval from the UK Stem Cell Bank,
and (ii) permissive in that once permission was granted research deemed illegal in some other
countries could be conducted. This ‘pro-science’ attitude in the United Kingdom (Hauskeller,
2004) found form in a local biological based on ‘institutionally accredited’ hES cells with a set
of instantiated regulatory mechanisms to pursue it.
Japan, in contrast, lacked a legal precedent on embryo research, as In Vitro Fertilisation
(IVF) practitioners had been self-regulated under guidelines from the Japan Society of
Obstetrics and Gynaecology. The first move on the derivation and use of hES cell lines came
when the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)
introduced guidelines in 2001:
Human embryos and ES cells shall be handled carefully and conscientiously without
violating human dignity, taking it into consideration that a human embryo is the
beginning of a human life and that human ES cells have the potential to differentiate into
any type of human cell.
(Ministry of Education, Culture, Sports, Science and Technology (Japan) (MEXT),
2001, Article 3)
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This regulatory form in principle sought to support hES research, while responding to the
growing concerns about the ethics of human embryo use. In practice, it resulted from a series
of political discussions among academic and non-academic intellectuals that corresponded
closely with debates taking place in the West, in particular the United States. The debate had
no involvement from broader Japanese publics, and as a result little attempt was made to
focus the regulatory policy on the ethical and religious specificities of the Japanese population
(Kato, 2005; Sleeboom-Faulkner, 2008). In adopting a perspective primarily based on the
debates in the West, the MEXT guidelines tightly regulated the derivation and use of hES cells
without prohibiting them. Recognizing therapeutic potential of hES cells, the Ministry also
ensured compliance with dominant socio-technical discourses emanating from the United
Kingdom and United States that tried to strike a balance between getting hES cell research
done and protecting human embryos.
Despite this attempted adoption of Western arrangements, many stem cell scientists in Japan
felt that in practice the MEXT guidelines were ‘irrationally’ tight (for example, Nakatsuji,
2007). The guidelines required all research proposals be vetted twice: first by the host
institutions’ Institutional Review Board (IRB) and second by MEXT itself. This two-tier
process generally took over a year to complete, if it was completed at all. Applications often
faltered as IRBs acted very cautiously in granting approval. They feared sending projects that
they had deemed suitable to MEXT’s final review in case MEXT chose to overturn their
decision. Failure in the second tier would reflect badly on both the IRB and the broader host
institution, particularly as research proposals were evaluated on two specific criteria: (i) their
ethical appropriateness, and (ii) the researcher’s technical and infrastructural capability.
If MEXT rejected a proposal, it implied either the IRB was not capable of making ethically
sound decisions or that the host institution lacked the necessary technical and infrastructural
capacity. So entrenched were these cautious attitudes that Nakatsuji’s laboratory at Kyoto
University remained the only group in Japan to establish hES cell lines for almost a decade.
The perceived lack of knowledge about hES cells shaped the precautionary approach of
MEXT’s 2001 guidelines. They prohibited any “clinical research applying human cells or cells
originated from [embryos] to the human body” as well as “utilization of them in medicine and
in its related fields” (MEXT, 2001, Article 2 (2)). This made basic research with hES cells
difficult and clinical research impossible, and it led many researchers in Japan to avoid hES
cells altogether and focus on mouse ES cells or other human cells instead. The Royal Society of
Engineering’s mission recognized this as a significant problem in 2003, stating they “were
surprised to see so much work on embryonic stem cells which, although interesting and
rewarding from a scientific point of view, cannot lead to any commercial or clinical advance in
the foreseeable future since Japanese regulations do not allow the therapeutic use of [hES]
cells” (RAoE, 2003, p. 53).
The unwillingness of the Japanese government to actively support hES cell research
remained evident in MEXT’s 2003 work program. The 5-year project – the Project for
Realization of Regenerative Medicine – was structured around three research areas: the
development of stem cell controlling techniques, the development of stem cell therapies and
the establishment of a stem cell bank for research purposes. None of these areas, including the
stem cell bank, highlighted hES cells explicitly. Instead the emphasis was on other kinds of
multipotent stem cells – including mesenchymal and cord blood stem cells – and it further
reinforced existing barriers to Japanese hES cell research. Acknowledging the restrictiveness of
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their own policies, MEXT advocated that a further revision of the guidelines were required.
While the committee to do so formed in December 2003, the revisions did not come into force
until early 2007 and once in place still failed to relax any of the conditions in the previous
document apart from a small provision allowing organizations beyond Nakatusji’s laboratory
to distribute its hES cell lines (MEXT, 2007a). This provision in principle made establishment
of a research-focused stem cell bank possible. A researcher we interviewed commented that
“the committee members were reluctant to make major change” unless they had “concrete
evidence” that hES cells work as invaluable clinical tools. While the Japanese approach had
targeted a vibrant and successful hES cell research portfolio modeled on the Western
approach, the practical instantiation of regulatory measures resulted in an overly restrictive
environment and led to stagnation in the field.
The contrast with the United Kingdom is stark. In 2002 Business Week presented the United
Kingdom as the world leader in stem cell technology with the declaration: “In stem cell
research, it’s rule Britannia” (cited in Franklin, 2005, p. 59). That year the Select Committee
of the House of Lords published a report in stem cell research that argued human “ES cells
have significant potential for developing new therapies” (House of Lords Stem Cell Research
Select Committee (UK) (HoL), 2002, p. 15). The report acknowledged the ethical discussion
over the status of the early embryo and agreed with the findings of the 1980s Warnock
Committee on IVF and embryology – that lead to the establishment of the HFEA – that
“[f]ourteen days [since fertilization] should remain the limit for research on early embryos”
(p. 48), in effect supporting the derivation of hES cells. To promote robust ethical practice in
this area, the committee endorsed the “Department of Health’s proposals to establish a stem
cell bank overseen by a steering committee, responsible for the custody of stem cell lines,
ensuring their purity and provenance and monitoring their use” (p. 50). By late 2002 the UK
Stem Cell Bank was established.
The House of Lords report also strongly encouraged continued funding for adult stem cell
research, which does not involve destroying embryos. While the conventional view in the
United Kingdom at the time was that adult stem cells exhibit limited therapeutic value
compared with hES cells because they were seen only capable of producing tissue of a related
cell type, the report noted ‘recent’ suggestions about the “[i]ncreased plasticity of adult stem
cells” (HoL, 2002, p. 14), reporting some feedback from the UK stem cell community that this
potential may make hES cell research “unnecessary” (p. 17). However, “the evidence of the
great majority of scientific and medical research organisations […] did not support this view”
as “it is unlikely that adult stem cells will fulfil all therapeutic needs” (p. 17). Furthermore,
“the full potential of adult stem cell research […] is unlikely to be realised without research on
ES cells […] because […] ES cells provide the only realistic means at present of studying the
mechanisms and controls of the processes of differentiation […] if safe and reliable therapies
are to be developed, a comparison with human ES cells must eventually be made” (p. 17). By
making these statements this key governmental body was both legitimizing and endorsing the
ethical use of hES cells.
By 2004 the UK Stem Cell Bank had established a state-of-the-art laboratory space to begin
receiving cell line deposits (Stacey, 2004; Stephens et al, 2008a, b). It was the first bank of its
kind in the world and operated with the ethical oversight ‘Steering Committee’ as recom-
mended in the House of Lords report. The committee is comprised of experts from
diverse backgrounds, including bioethicists, clinicians, stem cell scientists, disease group
Local biologicals and the politics of standardization
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representatives and sociologists; a range of expertise that committee members described in
interview as “most extraordinary”, “quite a challenge”, “hugely important” and even
something to “enjoy” (see also Stephens et al, 2008a).
Any laboratory in the United Kingdom with a HFEA license to derive hES cell lines had to
deposit them in the Bank. Laboratories in other countries were also permitted to deposit, and
several did. This led the Steering Committee to develop mechanisms for judging the
provenance and ethical suitability of potential deposits, and the appropriateness of potential
applications to access the cells from laboratories in the United Kingdom and abroad interested
in conducting research with deposited cell lines. In interview, committee members describe
how “with difficulty, the committee had to try to reach a consensus about what was really
essential and what wasn’t really essential”, a process inducing shared judgements about how
to recognize appropriate, and less frequently inappropriate, provenance: “I suppose the lesson
has been learnt that most of the time, most things are okay”. The criteria for ‘okay’ was
formulated in the Steering Committee’s (2005) Code of Practice for the use of human stem cell
lines that stated hES cell lines must “have been ethically sourced, with fully informed donor
consent, and that the cell lines present a valuable resource for the biomedical research
community” (p. 11). The importance not only of doing this work, but also of being seen to be
doing this work, was clearly understood. As one committee member noted in interview, their
committee “is there as a way of reassuring all sorts of different communities that there is a
regulatory framework; somebody is responsible for checking that this stuff is not going in
directions we don’t want it to go in”. As Hauskeller (2004) argues, these transparency
practices are an important characteristic of the British way of managing difficult issues, like
the ethics of human embryos.
The progressive establishment of an ethical source of hES cells in the United Kingdom
allowed focus to turn to pursuing this local biological in international stem cell science. The
2005 UK Stem Cell Initiative was established by the then Chancellor – Rt Hon Gordon Brown
– to “produce a vision and strategy to keep the UK at the leading edge of global stem cell
research over the next decade” (UK Stem Cell Initiative, 2005, p. 40). Their list of 10 strengths
of UK stem cell science included a supportive government, favorable ethical environment and
world-class researchers, and the UK Stem Cell Bank. While “crucial” the report notes the
Bank “is currently synonymous with embryonic stem cell lines” but “should ensure that it
develops expertise in … stem cell lines from all sources including adult stem cells” (p. 69).
Furthermore, it “should become the international centre in the development of stem cell
banking protocols, processes and techniques, such as cryogenics, infection control and Good
Manufacturing Practice (GMP)” (p. 69). The same report notes “[t]he Japanese Government
stance towards stem cell research is firmly in line with that of the UK” (p. 34) although
research “has remained to a large extent held back by the slow development of the regulatory
framework” (p. 35). This statement indicates an attempt to enroll Japanese stem cell research
into the UK local biological.
By the end of 2005 the Bank had taken deposits of the first hES cell lines derived in the
United Kingdom and were prepared to distribute them to any applicant approved by the
Steering Committee (UK Stem Cell Bank, 2005). Establishing the Bank had involved
challenges and had met some initial concerns within the UK stem cell community around its
role and the bureaucratic nature of its procedures (Stephens et al, 2011b). However there was
a growing sense within the community that the UK Stem Cell Bank was delivering an ethically
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robust mechanism for the establishment and distribution of hES cell lines that was emblematic
of the UK’s international stem cell science portfolio. As the Bank’s Director articulated in
interview, the United Kingdom saw itself as world leading and was keen for the rest of the
world to follow:
I think the UK model is increasingly being held up as the way to go. In California, in
China, in Korea they see that the work that’s being done is well grounded in making sure
that all the ethical, legal and technical issues have been dealt with before we’ve actually
launched into the work … I think this is something that the UK has really taken a lead
in, given other countries’ confidence in what they’re going to do.
However, an alternative model was emerging, which would also have international impact in
the field.
iPS Cells: A New Local Biological in Japan, Resistance within the
Established Local Biological of the United Kingdom
In November 2006, Yamanaka’s group at Kyoto University published work identifying four
genes addable to mouse fibroblasts that suggested pluripotent behavior (Takahashi and
Yamanaka, 2006). This induced pluripotency meant the cells could take on a broader
differentiation potential beyond the confines of its linage and thus mimic some of the growth
potential of hES cells. By late 2007, the international press reported two further groundbreak-
ing publications, one by Yamanaka’s group in Cell (Takahashi et al, 2007) and one by
Thompson and Yu at the University of Wisconsin-Madison in Science (Yu et al, 2007),
demonstrating similar successes with human fibroblasts. Using similar but different techni-
ques, both groups claimed to have produced pluripotent stem cells from human adult cells.
The media reported these developments as a breakthrough in the science, as much as the
ethical guardianship, of stem cells (for example, Cyranoski, 2007; Vogel and Holden, 2007;
Wilmut, 2009).
It is not difficult to see why these developments were greeted with such celebration.
As Takahashi and Yamanaka (2006) suggest in their first publication, iPS cells gave new life to
the therapeutic promises of hES cells, and to the regenerative medicine narrative that had
stimulated public imaginations around the world, but now without the need to destroy human
embryos. The invention, thus, could be framed as a decisive intervention into the religious and
moral controversy on the use of hES cells, which had resulted in complex regulatory structures
in some countries, including the UK StemCell Bank, and an outright ban of their study in others.
Furthermore, inducing pluripotency in the healthy cells of a diseased patient’s own cells
could minimize the chance of immunological rejection. A Japanese interviewee described this
as “the major advantage of using patient-derived stem cells” over hES cells. The new promise
offered was that iPS cells could provide all the functionality of hES cells without any of the
ethical drawbacks and possibly with less medical complications. While some researchers
remained cautious about these claims, many, including this interviewee, were confident that
“further study on the new pluripotent stem cells would soon demonstrate their safety and
confirm their clinical usefulness”. If the promise held true, it could lead to dramatic
reconfigurations of international stem cell policy as well as stem cell science.
Local biologicals and the politics of standardization
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The Japanese government was quick to recognize the importance of the iPS cell develop-
ment, and within a month of Yamanaka’s and Thomson and Yu’s publications, MEXT
published the policy document iPS Saibou (Jinkou-Tanousei Kansaibou) Kenkyu nado no
kasokuni muketa Sougou Senryaku (The General Strategy to Promote iPS Cell Research). The
Ministry was particularly concerned about the need to claim, and also protect, iPS cell
research as a ‘Japanese’ invention, with the competitive challenge from other countries most
visibly displayed in the simultaneous publication of successful human iPS cell research by
Japanese and American laboratories (Mikami, 2015). Attempting to address this, the General
Strategy listed plans to provide extensive support to Yamanaka’s group and others working
on iPS cells in the country. Among the plans were (i) the establishment of the Working Group
of Strategy for Stem Cells and Regenerative Medicine, (ii) the establishment of a central
research institution of iPS cells at Kyoto University and (iii) the development of a consortium
for iPS cell research (MEXT, 2007b). All of these plans were implemented within a couple of
months after the publication of the General Strategy, and Yamanaka became the central figure
in all three organizations – the Working Group, the Center for iPS cell Research and
Application (CiRA) and the iPS Network – indicating his rapidly increased importance in
Japanese stem cell research. Further financial support shifted toward iPS cell research, with
MEXT’s Project for Realization of Regenerative Medicine, the Council of Science and
Technology Policy, and two other government ministries backing these efforts. The response
was positive, with one interviewee declaring “the government support definitely improved the
research environment for stem cell scientists”. This more positive attitude, and the policy
changes allied to it, contributed to the emergence of a new Japanese biological based on
‘technically advanced’ pluripotent stem cells. While some resentment remained among scientists
working in other areas, stem cell science in Japan shifted into this new local biological and
diverted away from the ‘cell bank’ model being diffused globally from the United Kingdom.
While the announcement of human iPS cells received tremendous attention from scientific
and political communities internationally, some clear resistance to this new biological existed.
Some were critical of the low success rate of reprogramming; some were concerned about the
risk of using a gene called c-Myc as one of the transcription factors in reprogramming because
it is known as a cause of tumor formation; and others questioned whether the new cells can
be considered exact equivalent to hES cells (Holden and Vogel, 2008). Some of these technical
issues were responded to by new research findings: for example, Yamanaka’s group refined
the technique to produce iPS cells without the Myc-gene family (Nakagawa et al, 2008).
However, such technical advance also posed new questions about the technique. While
various new ways of inducing pluripotency to adult cells were being developed, some were
very different to the initial method (Okita et al, 2008; Stadtfeld et al, 2008; Zhou et al, 2009).
This raised questions about which approach is the best, in terms of both safety and efficiency
for clinical use. Furthermore, others argued reprogramming does not need to induce
pluripotency but remains useful if it only turns adult cells into one different lineage (Ieda et
al, 2010). Equally a new ethical focus emerged associated with iPS cells, which was different to
those framing hES cell debates: Zarzeczny et al (2009) articulate how new and existing issues,
including consent, reach-through rights, intellectual property, clinical translation and ethical
usage, could be relevant in this case. Quigley et al (2012) further complicate the issues in
considering the ramification of making germ cells through iPS cell techniques and the potential
of producing viable embryos, as has been achieved in mice.
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Responding to such initial reactions, the Japanese government adopted a strategy to
promote iPS cell research even further, and went so far as to relax existing guidelines that
had previously inhibited hES cell research. The rational for this relaxation was based on the
expected benefit for iPS cell research of allowing comparative hES cell work, because, as one
interviewee put it, “iPS cell and hES cell research are the wheels on a single axle”. In 2009,
MEXT revised its guidelines on hES cell research again, dividing them into two distinctive sets
of regulations: the Guidelines on the Derivation and Distribution of Human Embryonic Stem
Cells (MEXT, 2009a) and the Guidelines on the Utilization of Human Embryonic Stem Cells
(MEXT, 2009b). Under these new guidelines, researchers in Japan are in principle able to
conduct research on established hES cell lines by receiving the approval only from the IRB,
rather than going through the two-tier system. The guidelines were further revised in 2010,
when the creation of germ cells from both hES cells and iPS cells became permitted (MEXT,
2010a, b). The move toward ethically contentious territory of this particular revision
surprised many, including one of our interviewees who described the creation of germ cells
as “only a step away from creating embryos”. Together these changes demonstrate a dramatic
shift in the mode of governance in this field: in the pre-iPS years, Japan had not been able to
make a major change in its regulatory arrangements and it took 6 years to produce one small
revision of the guidelines; post iPS, in contrast, Japan acted swiftly and introduced a number
of rapid and radical regulatory revisions – all directed toward the advance of iPS cell research
–within a short period of time. Furthermore, in the interests of developing the Japanese iPS cell
research portfolio, procedures with hES cells that were previously prohibited were sanctioned
overturning years of restrictive regulation. This new local biological was taking hold.
The importance of the first publications on iPS cells was also recognized within the UK
regulatory system. Our ethnographic fieldnotes detail the first meeting of the UK Stem Cell
Bank Steering Committee – the Bank’s guidance and ethics oversight group – following the
announcement at which the potential impacts of iPS cells were discussed. In a highly
speculative discussion the interdisciplinary group considered what the technology could mean
for them and the Bank. The question was raised that if the Steering Committee’s primary role
is providing rigorous ethical guardianship for a sensitive biological material – hES cells – and
that the functionality of this material could now potentially be replaced by a non-controversial
substitute – iPS cells – then what need would there be for the Steering Committee in the future?
A range of views were expressed, but the idea was entertained that if iPS cells really did deliver
the functionality of hES cells and really did prove to be no more ethically sensitive than
existing adult stem cell procedures, then indeed the importance of the Steering Committee, and
by implication that of the UK Stem Cell Bank, might be significantly reduced. This was
couched in a number of questions over whether the claims concerning the value of iPS cells
were really reliable, and an acknowledgment that the Steering Committee remained respon-
sible for those hES cell lines already in circulation.
Through this context the UK Stem Cell Bank continued to work on developing best practice
in the technical and ethical guardianship of hES cell lines in global stem cell science. Perhaps
most noticeably, this occurred through their directorship of the International Stem Cell
Banking Initiative (ISCBI) from 2007 onwards. This project brought together representatives
from 17 countries, including Japan. As the UK Stem Cell Bank’s Director describes:
“I contacted the groups that I knew were actually banking cells, and who I felt were important
to be there to have a balanced meeting… the people aware of the shipping issues, the quality
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control issues, the technical difficulty of the actual work that’s being done, be aware of ethical
and other regulatory guidelines in their own country, so that we can get together and consider
the best practice for the banking, documentation, distribution, quality control and dealing
with ethical differences between different countries”. The consortium worked to share
procedures and encourage the establishment of new banks in countries where such an
institution did not exist (Crook et al, 2010). The first output from the project was delivering
consensus guidance for banking and supply of hES cells that was also argued to be applicable
to iPS cells (International Stem Cell Banking Initiative, 2010).
The progressive appearance of the Japanese local biological in the United Kingdom can be
observed in the 2010 version of the Steering Committee’s code of practice for the use of human
stem cell lines, noting that iPS cells “are believed to be like embryonic stem cells in many
respects” (Steering Committee for the UK Stem Cell Bank and For the Use of Stem Cell Lines,
2010, p. 8) although “[t]he full extent of iPS cells’ relationship to natural pluripotent stem cells
such as embryonic stem cells is still being assessed” (p. 8). It makes clear that while the deposit
of UK-derived hES cells is mandatory “[t]here is no such requirement to deposit iPS cells, fetal
or somatic stem cell lines within the UK Stem Cell Bank, although the Steering Committee will
consider applications to bank such lines where these are likely to provide a valuable resource
for research” (p. 9). iPS cell research is now common in the United Kingdom and the
regulatory position is equivalent to other adult stem cell research; meaning that there is no
specific role for the UK Stem Cell Bank or the HFEA to oversee its governance, unless
reproductive cells are being produced in which case the HFEA are again implicated.
While iPS cell research flourishes along with hES cell research in the United Kingdom, it can
be argued that, although to a lesser extent, the claim of the 2005 UK Stem Cell Initiative that
the UK Stem Cell Bank is “synonymous with embryonic stem cell lines” still holds. In early
2012, the Bank held 61 UK and 27 foreign-derived hES cell lines compared with one fetal and
no iPS cell lines. In practice, a great many UK researchers conduct iPS cell research, but the UK
local biological remains more closely tied to the hES cell trajectory. Similarly, the emergence of
the new Japanese biological was not an overnight event, and the influence of the UK Stem Cell
Bank remained observable in Japan. In 2009, the Japanese representative of the ISCBI in
interview emphasized the importance of being part of such an initiative – noting “no one
wants to stand alone” – and suggesting that hES cells might be safer than iPS cells for
clinical use. However, this type of opinion became progressively marginal following the
large government support for iPS cell research that allowed extensive study of its safety
and efficacy and increasingly convinced researchers in Japan that iPS cells are both ethical
and clinically useful. The same period saw little progress in hES cell research.
Contesting Local Biologicals: The Politics of Standardization in Stem
Cell Science
The story in this article so far has been one of initial similarity between the Japanese and
United Kingdom approaches to hES cell research and subsequent divergence. When the
mission of the Royal Society of Engineering visited Japan in 2003, the two countries were
pursuing strategies to establish themselves as world leaders in stem cell science, both
articulating a local biological around the promise of high-tech biology that could have its
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ethical challenges controlled by robust regulatory mechanisms, leading to national financial
reward, health gains and prestige (cf. Hauskeller, 2004). However, the initial responses from
the two governments were slightly different: while they both allowed hES cell research in
principle, particularly by introducing transparency in its governance, the Japanese regulation
proved unanticipatedly discouraging. As time passed, the difference became even clearer as the
United Kingdom put into place institutions and mechanisms to materialize this vision: the UK
Stem Cell Bank was established in 2003 promoting the ethical use of hES cells in the United
Kingdom and overseas. It actively engaged in international collaborations through its
directorship of the ISCBI, one part of a broader socio-technical arrangement that worked to
instantiate a vision of ‘institutionally accredited stem cells’. In contrast, regulatory complica-
tion remained in Japan for approximately 6 years, and, during this period, many Japanese
researchers avoided hES cell research. The emergence of human iPS cells in 2007 triggered the
beginning of a strategic divergence as Japan entered a period of rapid regulatory change as
afforded by a new iPS cell orientated vision, essentially opting for the ‘technically advanced
stem cells’ in response to the ethical and regulatory challenge of hES cells by pursuing this
embryo-free alternative.
Set within this context is a new politics of standardization, pitting hES cells and the UK
approach against iPS cells and the Japanese approach. Hauskeller and Weber (2011) have
already documented the complex relationship between hES and iPS cell technologies with their
ethnographic studies in the United Kingdom and Germany. In their study of laboratory
researchers, they describe how:
[for the laboratory researchers studied] the significance of iPS cells is constructed around
the fact that their potential is the same as hES cells as regards their pluripotency. Yet, in
arguing that research on iPS and hES cells must evolve in parallel, they are also framed
as different in that little is known about their status vis-à-vis hES cells. Implicitly, hES
cells are presented as having a stable status as scientific objects against which the
properties of iPS cells can be measured and determined.
(Hauskeller and Weber, 2011, p. 422, emphasis in original)
This is a common framing of the issues as found in both Germany and the United Kingdom,
indicating what Hauskeller and Weber (2011, p. 427) call “global discursive repertoires”
formed through international exchange of bioethical discourses and technical knowledge.
Networks including the International Stem Cell Initiative and stem cell banks such as that in
the United Kingdom are identified as key actors in facilitating this exchange. We identify
similar constructions about the relationships between hES and iPS cells within our regulatory
settings.
Our comparison, however, questions what form such discursive repertoires take as well as
to what extent they really are global. The framing identified in the United Kingdom and
Germany comparison suggests that iPS cell researchers bear the burden of proving their
equivalence to hES cells. Behind this burden is the assumption that iPS cells are artificial
mimicry of natural hES cells, as also observed by Hauskeller and Weber:
These accounts convey three important notions that characterise hES cells in
relations to iPS cells: (a) hES cells are portrayed as established objects of research
practice, especially suited as models for experimental control; (b) hES cells become
Local biologicals and the politics of standardization
13© 2015 Macmillan Publishers Ltd. 1745-8552 BioSocieties 1–20
the “normal” pluripotent stem cells. This normalisation takes place within the linear
model of development that takes the hES cell as representing an early stage of
differentiation from which all latter cell types derive and which is defined by
“natural” pluripotency; (c) the pluripotency of iPS cells as the product of genetic
intervention in the laboratory is implicitly presented as not natural, an artificially
produced property. This pluripotency of iPS cells needs to be checked against the
“normal” pluripotency of hES cells.
(Hauskeller and Weber, 2011, p. 423)
This is also explicit within the UK Stem Cell Bank’s Steering Committee’s 2010 version of the
code of practice for the use of human stem cell lines in the United Kingdom: “[t]he full extent
of iPS cells’ relationship to natural pluripotent stem cells such as embryonic stem cells is still
being assessed” (Steering Committee for the UK Stem Cell Bank and For the Use of Stem Cell
Lines, 2010, p. 8, emphasis added). By defining iPS cells in relation to hES cells the United
Kingdom approach renders the Japanese biological as an underdefined contestant to their
‘institutionally accredited’ pluripotent stem cells.
Importantly, the construction of hES cells as natural assumes a particular set of meanings
and constellation of socio-technical resources in its accomplishment. Embedded within this is
the notion that hES cells are natural because, unlike iPS cells, they do not require genetic
modification techniques. However, outside of laboratory settings hES cells only exist during a
transitional state early in embryo development before they differentiate into cells with less
differentiation potential in the course of its ‘natural’ development after fertilization. In the
laboratory context, the cells are removed from embryos and artificially immortalized.
As Landecker observed for HeLa cells, the cells are “freed from the bounds of the body” and
simultaneously “from the limits of the originating organism’s life span” (2007, p. 11).
Therefore, despite the common assumption about their naturalness, hES cells can also be
understood as unnatural. The higher chance of immunological rejection after transplantation
further supports this understanding of their unnaturalness, at least, if inserted in a patient’s
body (cf. Lock, 2002). The assertion of ‘naturalness’, and any subsequent comparative
criterion premised upon it, is a key component of the politics of standardization in global stem
cell science.
There has been a struggle to standardize hES cells since they were first derived. Apart
from their provenance in human embryos, the only feature that defines hES cells may be
their pluripotency: the ability to differentiate into many cell lineages (Webster and
Eriksson, 2008). However, there is no marker or set of markers uniquely expressed in
hES cells that defines their pluripotency, and they can only be tested by seeing if they form
teratomas in animal models. If a standard marker did exist, as Eriksson and Webster
(2008) point out, it would serve as a performative standard establishing the potentiality of
hES cells to be other cells in the future without relying upon animal teratoma tests. Such a
standard would be important in our context because the same marker could then be used
to test if pluripotency of iPS cells is underpinned by the same biological mechanisms as that
of hES cells, and thus the ‘articifial’ stem cells can be tested if they are equivalent to the
‘natural’ stem cells. Currently this remains impossible as different researchers use varying
techniques to derive hES cells and deploy different markers to test their state, just as they
do to produce iPS cells and to test their state. An international attempt to address this gap
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and reach agreement on markers for hES cells, led by the International Society for Stem
Cell Research, failed to identify an agreed standard.
In this context, the activities of the UK Stem Cell Bank become important. While scientists
may not be able to agree on performative standards, they seem to be more willing to agree
procedural standards. By curating a large number of hES cell lines and improving their
culturing techniques, the UK Stem Cell Bank is in a strong position to minimize the gap
between different procedures adopted in various locals. It also provides technical support to
the recipients of hES cell lines and, by so doing, disseminates its techniques. Furthermore, the
assessment at the Bank to accept established cell lines and to distribute them internationally
based on ethical and technical criteria reinforces their particular set of standards for the
conduct and nature of hES cell research globally. Any international laboratory that wants to
deposit or access a cell line with the UK Stem Cell Bank must demonstrate to its Steering
Committee that it complies with their standards. Furthermore, the acceptance of a hES cell line
at the UK Stem Cell Bank can be ascribed as a guarantor of ethical legitimacy in other
jurisdictions, as is the case with funding from the California Institute of RegenerativeMedicine
(see Hammond-Browning and Stephens, 2013). This spreading of the UK biological is further
increased through the UK Stem Cell Bank’s directorship of the ISCBI that addresses both
technical and ethical best practice. Together with the less-standardized domain of performative
standards, the UK Stem Cell Bank has been aiming to produce a standardized package of hES
cell research, which would introduce institutional alignments across different local contexts and
lead to increased do-ability of hES cell research internationally (Fujimura, 1987).
If successful these processes of standardization would be powerful social devices and, as Star
(1991) observes, non-compliance with the standards leads to marginalization incurring extra
social burdens for the marginalized. By treating hES cells as the standard type of pluripotent
cells, the burden of proof is imposed upon iPS cell researchers. Furthermore, a standardized
hES cell could also serve as a boundary object, able to cross between local contexts without
losing its significance (Star and Griesemer, 1989). Such high mobility would be an important
aspect of any global biological, applying equally to the stem cell case. As Eriksson and
Webster (2008) argue, standards in stem cell science “function as stabilizing and enabling
tools, and standardization is a common and often successfully applied strategy in new and
emerging fields of research, and indeed, acts to recruit and coordinate participants in the field”
(p. 64). The discourse of recognizing hES cells as the standard of pluripotency is so powerful
that even the Japanese biological has not been able to dismiss it in instantiating its vision of
‘technically advanced’ stem cells, as witnessed in their relaxation of hES cell guidance in the
post-iPS era.
In the same way, the discussion about the clinical potential of iPS cells cannot be ignored in
instantiating the vision of ‘institutionally accredited’ stem cells in the United Kingdom, as
evidenced in the reaction from the UK Stem Cell Bank. Even if hES cells were to become more
technically stabilized and ethically assured, there remain other ways the clinical advantage of
iPS cells over hES cells could be established. One possible example is the potential therapeutic
use of patients’ own iPS cells mitigating immunological-compatibility issues, widely known as
autologous cell therapy (Takahashi and Yamanaka, 2006). That noted, in Japan, MEXT has
been moving away from this autologous cell therapy model, considering it too expensive and
time-consuming. Instead, Japanese researchers now work to establish a hospital-based iPS cell
bank to distribute clinically useful non-patient specific iPS cell lines for therapeutic use
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(Cyranoski, 2012). While the iPS cell bank currently lacks the transparency in governance and
the breadth of functionality seen at the UK Stem Cell Bank, we suggest it may still develop to
become recognized as a stable site for sourcing safe and efficient cell lines, should further
research demonstrate the clinical usefulness of iPS cells. This could furnish the iPS cell field
with a set of de facto standards (see Sengoku et al, 2011) or design standards (Eriksson and
Webster, 2008) that become dominant through serving a majority without attaining formal
agreement from all within a community. If achieved, the impact of this on the UK Stem Cell
Bank could be significant. In the short term, the threshold that individual applications to the
UK Stem Cell Bank would need to meet in terms of establishing that their proposed hES cell
research could not be accomplished through other means would be raised, with applicants
needing to prove an iPS cell project is not a viable alternative (Hammond-Browning and
Stephens, 2013). In the longer term, questions could be raised about the very necessity of the
ethical guardianship role played by UK Stem Cell Bank, beyond overseeing those hES cell lines
already in circulation.
These moments – the work on technical standardization in the United Kingdom and the
establishment of an iPS cell bank in Japan – are significant moments because they mark a
curvature in the post-2007 trajectories in the two countries. While the period immediately
following the emergence of human iPS cells saw both the United Kingdom and Japan
journeying on different and distinctive paths, we subsequently see both countries coming full
circle to challenge and inform each other. For the UK socio-technical arrangements to
globalize, they must move beyond their institutional accomplishments to grapple with the
technical feats of establishing a standardized set of markers that validate the pluripotency of
hES cells. If this were achieved, the increased do-ability of hES cell research across different
contexts could undermine the Japanese local biological and limit the significance of iPS cell
invention. In this case, hES cells could globalize as the UK biological becomes internationally
accepted and totalizes the field of stem cell science. Alternatively, for the Japanese socio-
technical arrangements to globalize, they must attain a level of institutional stability to assert
the clinical usefulness of iPS cell therapies in the medical system. If this were achieved, iPS cells
could be presented as having a stable status as clinical objects, in contrast to Hauskeller and
Weber’s (2011) account of hES cells as scientific objects (see also Wainwright et al, 2009 for
related discussion). The institutionalized guardianship of hES cell ethics, represented by the
work of the UK Stem Cell Bank, could be deemed unimportant, or even unnecessary. In this
case, iPS cells could globalize as the Japanese biological becomes diffused and dominating in
this international field.
Conclusion
Stem cell science exhibits ongoing expansion. The establishment of the first hES cell line in
1998 served as the trigger, and the potential of stem cells for therapeutic use, which is
largely underpinned by the pluripotent character of hES cells, is no doubt one major reason
for it. However, more importantly, the expansion would not have been possible if stem cell
science did not attract political and economic interests on a global scale, that is, in
Franklin’s (2005) term, the emergence of the global biological enterprise. The strong
political commitments from national governments simultaneously created the divergence of
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local socio-technical arrangements for stem cell sciences and reinforced the aspect of stem
cells as local biologicals.
In seeing scientific, medical and economic potential of hES cell research, the UK government
adjusted the regulatory framework established during the debate on IVF and decided to
instantiate its vision of ‘institutionally accredited’ pluripotent stem cells. This vision was
further substantiated by several policy reports and the UK Stem Cell Bank established in 2003
was a key component in its pursuit of bringing this locally emerged vision onto the global
stage. The Bank soon became recognized as the archetype of hES cell governance and its
members contributed to developing internationally standardized protocols for handling hES
cells. Thus, the UK local biological was successful in not only legitimizing hES cell science in its
local context but also building the United Kingdom’s reputation internationally and convin-
cing other countries to follow its approach. The first challenge to this model came with the
creation of human iPS cells in 2007. Japan, which failed to create a successful local biological
based on a similar vision of ‘institutionally accredited’ hES cells, rapidly made its decision to
commit to the new reprogramming technique and created a new vision based on iPS cells. In
contrast to the UK approach, this Japanese vision can be understood as the technical response
to the ethical challenge of hES cells shared in global stem cell science, summarized as
‘technically advanced’ pluripotent stem cells. Today, these two local visions engage in the
politics of standardization, undermining the significance of the other to present its global
value.
This politics allows us to recognize a local biological as an assemblage inevitably informed
by various national socio-technical arrangements: some parts of arrangements developed in
one national context transgress national boundaries becoming reframed in another. In this
regard we take a step further than Franklin and her account of the local/global biological, by
asserting the ways in which the local biologicals of Japan and the United Kingdom are
connected, in this instance progressively through processes of standardization and the
question about ‘naturalness’. In the United Kingdom, efforts to shape international standardi-
zation initiatives for hES cells seeks to assert this cell type as the gold standard, in part
premised upon a particular construction of the ‘naturalness’ of hES cell lines. If successful, this
would raise the barrier for establishing iPS cells as appropriate candidates to replace them.
In contrast, researchers in Japan are now trying to demonstrate the clinical usefulness of iPS
cells and establish a cell bank as a stable source of these. If successful, this would question the
absolute necessity of hES cell research and hence the importance of the UK Stem Cell Bank as
their ethical guardian.
Here, we also see the incompleteness of the two local biologicals evident in the United
Kingdom and Japan. On the one hand, the UK local biological was premised upon
institutional aspects of hES cell governance invoking the naturalness of hES cells, but now
technical development is required to establish the cells as a gold standard. The Japanese local
biological, on the other hand, was built upon the technical advancement in stem cell science,
namely the reprogramming technique for iPS cells, but a form of institutional stability
ensuring its safety as well as its cost effectiveness in medicine is now critical to confirm iPS
cells’ clinical usefulness. Therefore, we suggest that, while the two countries headed off in
distinctive directions in the mid-2000s, they are now incentivized to progress in directions that
they had not pursued then, namely creating an equivalent to the socio-technical arrangements
instantiated in the other.
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